Novo Nordisk AS (Novo Nordisk), a subsidiary of Novo Holdings AS, is a healthcare company focused on discovering, developing, and manufacturing of innovative biological medicines. It focuses on advancing drugs for the treatment of diabetes and other serious chronic conditions, including hemophilia, human growth hormone (HGH) disorders, and obesity. The company’s portfolio includes pre-filled delivery systems for insulin; glucagon hypokit; cartridge; needles; vials; insulin; estradiol for hormone replacement; recombinant drugs for hemophilia; glucagon; and oral antidiabetic agents. the company markets its products through subsidiaries in North America, Europe, Asia, Latin America, Africa, the Middle East and Australia. Novo Nordisk is headquartered in Bagsvaerd, Denmark.

Headquarters Denmark

Address Novo Alle 1, Bagsvaerd, 2880


Telephone 45 44 448888

No of Employees 50,816

Industry Pharmaceuticals and Healthcare

Ticker Symbol & Exchange NOVO B (CPH)

Revenue (2020) $22.4B 10.9% (2020 vs 2019)

EPS XXX

Net Income (2020) XXX 13.3% (2020 vs 2019)

Market Cap* $175.1B

Net Profit Margin (2020) XXX 2.2% (2020 vs 2019)

* As of and is in US$

Access premium data and analytics for Novo Nordisk AS

1,400+

Clinical Trials

Determine Novo Nordisk AS go-to-market proposition and gain insight into the company’s clinical operations, recruitment, and trial strategy.

600+

Catalyst Calendar

Proactively evaluate Novo Nordisk AS’s catalyst impacts to stay ahead of the competition & improve corporate planning. Bolster business development with timely opportunities.

470+

Lead Sheet

Understand when and why to target accounts of prospective leads, as well as who to reach out to, drawing on intelligence for Novo Nordisk AS’s relevant decision makers and contact details.

180+

Pipeline Drugs

Identify which of Novo Nordisk AS’s products will be commercialized, helping you to better contend with shifting product portfolios, and allowing you to stay one step ahead of the market.

140+

Insights

Remove risk and uncertainty, gain a competitive edge and secure actionable leads with access to company-related investigative journalist content.

50+

Marketed Drugs

Understand Novo Nordisk AS’s commercialized product portfolio to stay one step ahead of the market.

40+

Sales & Consensus Forecasts

Understand the current and future drug revenue for Novo Nordisk AS and assess market opportunity for new entrants with patient population 8-year forecasts.

40+

Regulatory Milestones

Track drug and patent expiries along with geographies impacted.

460+

Install Base

Install Base provides a holistic and a granular view of the IT product/service deployments from leading vendors. Explore IT infrastructure categories, solution and product/service areas deployed by a prospect.

70+

Medical Clinical Trials

A database of clinical trials planned, currently ongoing, completed, suspended, withdrawn, and terminated in countries around the world.

30+

Medical Marketed Products

A database of medical devices currently for sale around the world. Devices that have been approved by a regulatory authority are included.

13+

IT Services Contracts

Improve competitive bidding with insights into all publicly disclosed IT services contracts for Novo Nordisk AS (including IT outsourcing, business process outsourcing, systems integration & consulting and more).

11+

Medical Pipeline Products

A database of medical devices that are in the process to get approved for sale around the world. Devices that are in development, through to those in the approval process are included.

1

ICT Spend & Tech Priorities

IT Client Prospector provides intelligence on Novo Nordisk AS’s likely spend across technology areas enabling you to understand the digital strategy.

Subscribe to Company Analytics & gain access to premium industry data & analytics Subscribe to Company Analytics & gain access to premium industry data & analytics Start Here

Products and Services

Products Brands
Diabetes Delivery Systems: Tresiba
Insulin pens Ryzodeg
Pre-filled insulin delivery systems Xultophy
XXX XXX
XXX XXX
XXX XXX
Subscribe to Company Analytics for access to more products & services data Subscribe to Company Analytics for access to more products & services data Learn More

History

History section provides information on new products, mergers, acquisitions, expansions, approvals, and many more key events.

Year Event Description
2022 New Products/Services In September, the company launched OTC HRT treatment in the UK.
2022 Contracts/Agreements In September, the company entered into an agreement to acquire Forma Therapeutics for US$1.1 billion.
2022 Contracts/Agreements In September, the company and Octagon Therapeutics entered into a research collaboration agreement on inflammatory diseases.
Dive into past operations, including product releases, deals, acquisitions & more Dive into past operations, including product releases, deals, acquisitions & more Get Started
Image for loader

Competitor Comparison

Key Parameters Novo Nordisk AS Johnson & Johnson Pfizer Inc F. Hoffmann-La Roche Ltd Novartis AG
Headquarters Denmark United States of America United States of America Switzerland Switzerland
City Bagsvaerd New Brunswick New York Basel Basel
State/Province - New Jersey New York - -
No. of Employees 50,816 141,700 79,000 100,920 108,000
Entity Type Public Public Public Public Public
Benchmark the company against the market with exclusive information on key competitors Benchmark the company against the market with exclusive information on key competitors Find out more
Chart Financial activity with access to more key stats Chart Financial activity with access to more key stats Find out more
Executives
Name Position Board Since Age
Helge Lund Chairman Executive Board 2018 60
Lars Fruergaard Jorgensen Chief Executive Officer; President Executive Board 2017 56
Karsten Munk Knudsen Executive Vice President; Chief Financial Officer Senior Management 2018 51
Marcus Schindler Head - Research & Early Development; Executive Vice President; Chief Scientific Officer Senior Management 2021 56
Jeppe Christiansen Vice Chairman Executive Board 2013 63
Non Dignissim Eros Proin vel Convallis 2022 XX
Non Dignissim Eros Proin vel Convallis 2022 XX
Non Dignissim Eros Proin vel Convallis 2022 XX
Gain more insight into company management & employee structure with Company Analytics Gain more insight into company management & employee structure with Company Analytics Subscribe
Still looking?

Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.

Explorer

Access more premium companies when you subscribe to Explorer